Drug combo halted early in High-Risk blood disorder trial
NCT ID NCT04812548
Summary
This study aimed to test the safety and effectiveness of a new drug, sabatolimab, when given with two other drugs (azacitidine and venetoclax) for adults with high-risk myelodysplastic syndrome (MDS), a serious bone marrow disorder. The trial was designed for patients who were not suitable for intensive chemotherapy or a stem cell transplant. The sponsor, Novartis, decided to stop enrolling new participants early, so only the initial safety-check part of the study was completed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Brasschaat, 2930, Belgium
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Nice, 06202, France
-
Novartis Investigative Site
Düsseldorf, 40479, Germany
-
Novartis Investigative Site
Stuttgart, 70376, Germany
-
Novartis Investigative Site
Alexandroupoli, Evros, 681 00, Greece
-
Novartis Investigative Site
Pátrai, 265 00, Greece
-
Novartis Investigative Site
Nyíregyháza, 4400, Hungary
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Barcelona, Catalonia, 08036, Spain
Conditions
Explore the condition pages connected to this study.